Please use this identifier to cite or link to this item:
|Authors:||Monath, Thomas P.|
Vasconcelos, Pedro F. C.
|Affilliation:||Hookipa Biotech AG. Vienna, Austria / PaxVax Inc. Menlo Park Redwood City, CA, USA.|
Instituto Evandro Chagas. National Reference Laboratory of Arboviruses. Department of Arbovirology and Hemorrhagic Fevers. Ananindeua, Brazil / Instituto Evandro Chagas. National Institute of Science and Technology for Viral Hemorrhagic Fevers. Ananindeua, Brazil / Instituto Evandro Chagas. PAHO/WHO Collaborating Center for Arbovirus Research and Diagnostic Reference. Ananindeua, PA, Brazil / Pará State University. Belém, PA, Brazil.
|Abstract:||Yellow fever, a mosquito-borne flavivirus disease occurs in tropical areas of South America and Africa. It is a disease of major historical importance, but remains a threat to travelers to and residents of endemic areas despite the availability of an effective vaccine for nearly 70 years. An important aspect is the receptivity of many non-endemic areas to introduction and spread of yellow fever. This paper reviews the clinical aspects, pathogenesis, and epidemiology of yellow fever, with an emphasis on recent changes in the distribution and incidence of the disease. Recent knowledge about yellow fever 17D vaccine mechanism of action and safety are discussed.|
|Citation:||MONATH, Thomas P. ; VASCONCELOS, Pedro F. C. Yellow fever. Journal of Clinical Virology, n. 64, p. 160-173, Mar. 2015.|
|Appears in Collections:||INI - Artigos de Periódicos|
Files in This Item:
|ve_Monath_Thomas_etal_INI_2015.pdf||2.87 MB||Adobe PDF||Request a copy|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.